Zacks Investment Research on MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...
It crushed analyst estimates on both the top and bottom lines. This, despite significant erosion in both metrics. For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results